Core Laboratories Inc. (CLB)
| Market Cap | 773.61M |
| Revenue (ttm) | 526.52M |
| Net Income (ttm) | 29.67M |
| Shares Out | 46.05M |
| EPS (ttm) | 0.63 |
| PE Ratio | 26.75 |
| Forward PE | 23.74 |
| Dividend | $0.04 (0.24%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 249,902 |
| Open | 17.53 |
| Previous Close | 17.29 |
| Day's Range | 16.68 - 17.68 |
| 52-Week Range | 9.72 - 20.36 |
| Beta | 1.16 |
| Analysts | Hold |
| Price Target | 12.50 (-25.6%) |
| Earnings Date | Apr 29, 2026 |
About CLB
Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and natural gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize pr... [Read more]
Financial Performance
In 2025, Core Laboratories's revenue was $526.52 million, an increase of 0.51% compared to the previous year's $523.85 million. Earnings were $29.67 million, a decrease of -5.51%.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CLB stock is "Hold." The 12-month stock price target is $12.5, which is a decrease of -25.60% from the latest price.
News
CORE LAB ANNOUNCES IMPACT OF THE MIDDLE EAST CONFLICT TO FIRST QUARTER 2026 GUIDANCE
HOUSTON, March 23, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") continues to evaluate and monitor the evolving geopolitical conflict in the Middle E...
Core Laboratories Earnings Call Transcript: Q4 2025
Fourth quarter revenue rose 3% sequentially and 7% year-over-year, with strong international demand offsetting US softness. Margins were pressured by tariffs, bad debt, and weather disruptions, but capital discipline and share buybacks continued. Guidance for Q1 2026 anticipates revenue of $124–$130 million and EPS of $0.11–$0.15.
CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported fourth quarter 2025 revenue of $138,300,000. Core's operating income was $15,...
CORE LABORATORIES ANNOUNCES TIMING OF FOURTH QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL
HOUSTON, Jan. 5, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its fourth quarter 2025 conference call for investors and analysts at 7:30 a.m. CST / 8:30 a.m. EST on February 5, 2026.
Core Laboratories Earnings Call Transcript: Q3 2025
Q3 2025 saw over 3% sequential revenue growth, margin expansion, and strong international demand, with $5 million returned to shareholders via buybacks. Outlook remains constructive, with Q4 revenue projected at $132–$136 million and EPS of $0.18–$0.22.
CORE LAB REPORTS THIRD QUARTER 2025 RESULTS
HOUSTON, Oct. 22, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2025 revenue of $134,500,000. Core's operating income was $20,...
CORE LABORATORIES ANNOUNCES STRATEGIC ACQUISITION OF BRAZIL-BASED SOLINTEC
HOUSTON , Sept. 30, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") announced today the acquisition of Brazil-based integrated geological services company, Solintec.
CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL
HOUSTON, Sept. 24, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its third quarter 2025 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m. EST on October 23, 2025...
Core Laboratories Earnings Call Transcript: Q2 2025
Q2 2025 saw 5% sequential revenue growth, margin expansion, and strong free cash flow, with international demand and new technology deployments offsetting U.S. market softness. Guidance for Q3 projects stable revenue and continued focus on shareholder returns.
CORE LAB REPORTS SECOND QUARTER 2025 RESULTS
REVENUE OF $130.2 MILLION, UP 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR OPERATING INCOME OF $15.3 MILLION; EX-ITEMS, $14.5 MILLION, UP OVER 23% SEQUENTIALLY AND DOWN 11% YEAR-OVER-YEAR OPERATING MARGINS...
CORE LABORATORIES ANNOUNCES TIMING OF SECOND QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL
HOUSTON , June 24, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter 2025 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m.
CORE LABORATORIES ANNOUNCES OPENING OF UNCONVENTIONAL CORE ANALYSIS LABORATORY IN SAUDI ARABIA
HOUSTON , May 7, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") is pleased to announce the opening of its new Unconventional Core Analysis Laboratory ...
Core Laboratories Earnings Call Transcript: Q1 2025
Q1 2025 saw revenue and earnings decline due to seasonality and expanded sanctions, but operational efficiencies and cost controls helped mitigate impacts. Guidance for Q2 anticipates revenue growth and margin improvement, with international markets expected to remain resilient.
CORE LAB REPORTS FIRST QUARTER 2025 RESULTS
REVENUE OF $123.6 MILLION, DOWN 4% SEQUENTIALLY AND 5% YEAR-OVER-YEAR OPERATING INCOME OF $4.4 MILLION; EX-ITEMS, $11.8 MILLION, DOWN 25% SEQUENTIALLY AND 21% YEAR-OVER-YEAR OPERATING MARGINS, EX-ITEM...
CORE LABORATORIES ANNOUNCES TIMING OF FIRST QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL
HOUSTON, March 24, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its first quarter 2025 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m. EST on April 24, 2025.
Core Laboratories Earnings Call Transcript: Q4 2024
Q4 2024 saw a slight revenue decline sequentially but full-year growth in revenue, operating income, and EPS. Debt reduction and free cash flow generation were strong, with international markets driving future growth despite ongoing geopolitical and weather-related headwinds.
CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS
FOURTH QUARTER REVENUE OF $129.2 MILLION, DOWN 4% SEQUENTIALLY AND UP SLIGHTLY YEAR-OVER-YEAR FOURTH QUARTER OPERATING INCOME OF $14.2 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 14% SEQUENTIALLY, UP 4% YE...
CORE LABORATORIES ANNOUNCES TIMING OF FOURTH QUARTER 2024 EARNINGS RELEASE AND CONFERENCE CALL
HOUSTON , Jan. 3, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its fourth quarter 2024 conference call for investors and analysts at 7:30 a.m. CST / 8:30 a.m.
Clinical Chemistry and Immunoassay Industry Forecast Report to 2028: Integrated and Scalable Core Lab Solutions Driving Transformational Growth
Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Clinical Chemistry and Immunoassay Industry, Global, 2023-2028" report has been added to ResearchAndMarkets.com's offering. This analysis examines the gl...
Core Laboratories Earnings Call Transcript: Q3 2024
Revenue and margins improved sequentially and year-over-year, driven by international growth and technology deployment, despite geopolitical and weather-related headwinds. Free cash flow was used to reduce debt, and guidance anticipates continued international strength and a rebound in U.S. activity in 2025.
CORE LAB REPORTS THIRD QUARTER 2024 RESULTS
THIRD QUARTER REVENUE OF $134.4 MILLION, UP 3% SEQUENTIALLY AND OVER 7% YEAR-OVER-YEAR THIRD QUARTER OPERATING INCOME OF $19.8 MILLION; EX-ITEMS, $18.2 MILLION, UP 11% SEQUENTIALLY AND 14% YEAR-OVER-Y...
CORE LABORATORIES' THIRD QUARTER 2024 WEBCAST AT 7:30 A.M. CDT / 8:30 A.M.
HOUSTON, Sept. 24, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its third quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on October 24, 2024.
Core Laboratories Earnings Call Transcript: Q2 2024
Q2 2024 saw slight revenue growth, improved margins, and strong free cash flow, with net debt reduced by over 10%. International demand is robust, but U.S. onshore activity remains soft due to low gas prices and consolidation. Q3 guidance projects continued margin strength and revenue growth.
CORE LAB REPORTS SECOND QUARTER 2024 RESULTS
SECOND QUARTER REVENUE OF $130.6 MILLION, UP SLIGHTLY SEQUENTIALLY AND YEAR-OVER-YEAR SECOND QUARTER OPERATING INCOME OF $16.0 MILLION; EX-ITEMS, $16.4 MILLION, UP 10% SEQUENTIALLY AND 5% YEAR-OVER-YE...
CORE LABORATORIES' SECOND QUARTER 2024 WEBCAST AT 7:30 A.M. CDT / 8:30 A.M.
HOUSTON , June 25, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its second quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m.